Not checked for notices yet.

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

Toshio Fujino, Kenichi Suda, Takamasa Koga and 7 more

Journal of Hematology & Oncology · 2022

doi:10.1186/s13045-022-01299-z

Cited by papers we hold 2

Therapeutic advances of targeting receptor tyrosine kinases in cancer · 2024
No notice
Molecular targeted therapy for anticancer treatment · 2022
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.